Acotiamide
Phase 3Small molecule
Acotiamide is one of 56 small molecule programs targeting Dyspepsia. It is currently in Phase 3.
3
Indications
4
Total Trials
2
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
49 competitors in Age
#DrugCompanyPhaseTrials
1Actigall
AbbVieApproved
Rapamune
PPrism Pharmaceuticals
Approved
Decadron
AAspen Global Incorporated
Phase 2
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Rezurock
KKadmon, a Sanofi Company
Phase 2
Venclexta
AbbViePhase 1
Acotiamide
GGetz Pharma
Phase 3
Evorpacept
AALX Oncology Inc.
Phase 2
APG-115
Ascentage Pharma Group Inc.Phase 2
APG-2575
Ascentage Pharma Group Inc.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Age1 trial
Comparing Acotiamide and Itopride for the Management of Indigestion
Not yet recruiting·—·Phase 4·NCT07449689·368 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acotiamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- GGetz Pharma